• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

News & Events / Events

Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management  

To influence patient outcomes, evidence must address unmet needs, align with the medical and commercial strategy, and provide value to healthcare providers (HCPs) and patients. Integrated evidence generation planning that encompasses real-world evidence (RWE), health economics and outcomes research (HEOR), and clinical studies is the best approach for gathering and synthesizing data to support clinical and payer decision-making. Cross-functional teams that span Market Access, HEOR, RWE, Commercial, and Medical Affairs blend broad perspectives to foster value-based integrated planning. Now that Medical Affairs contributes earlier in the integrated evidence generation planning process, patient and HCP evidence needs can be incorporated into studies earlier, ensuring more meaningful and actionable data generation. Through such cross-functional partnership, the hope is that integrated evidence generation planning can become more targeted, valuable, and efficient in generating data that will fulfill disease- and asset-driven unmet needs.

The
objectives of this webinar are:

  • To understand the importance of creating a compelling integrated evidence generation plan that addresses the needs of multiple stakeholders.
  • To brainstorm on the challenges created by evolving cross-functional teams owning the evidence generation plan.
  • To offer solutions to address those challenges and build evidence generation capabilities across teams.
  • To align on key success factors to creating an implementable evidence plan that addresses evidence gaps and ensures launch and reimbursement success from a multi-stakeholder perspective.

Speakers: 

  • Rosemary Jose, PhD, Executive Director & Europe Lead, Strategic Market Access, OPEN Health
  • Dana Franznick, PharmD, Senior Director, Medical Strategy, OPEN Health
  • Seema Haider, MSc, PhD (ABD), Head, Emerging Markets, Value Evidence & Outcomes, GSK
  • Sonia Pulgar, MPH, Head, Global HEOR & Market Access (previously Humacyte, Seagen, Ipsen)

Date: February 27, 2024

Time: 9:00 AM ET/ 3:00 PM CET

Details and registration

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top